Characteristics and survival of patients with non-small cell lung cancer treated with immune-checkpoint inhibitors in the real-world: experiences from Bergen, Norway

Acta Oncol. 2022 Jul;61(7):814-818. doi: 10.1080/0284186X.2022.2068969. Epub 2022 Apr 28.
No abstract available

Publication types

  • Letter

MeSH terms

  • Antineoplastic Agents, Immunological* / therapeutic use
  • Carcinoma, Non-Small-Cell Lung* / drug therapy
  • Humans
  • Immune Checkpoint Inhibitors
  • Lung Neoplasms* / drug therapy
  • Nivolumab / therapeutic use
  • Retrospective Studies

Substances

  • Antineoplastic Agents, Immunological
  • Immune Checkpoint Inhibitors
  • Nivolumab